Apimeds corrects Merger Agreement errors: Preferred Stock issuance rises to 90.9% of equity

Apimeds Pharmaceuticals US, Inc.

Corrected Merger Agreement removes Sections 2.05(b)/(d) (director appointment).
Common Stock Cap corrected from 29.9% to 0% of Acquiror Common Stock outstanding.
Preferred Stock issuable to Company stockholders corrected from 61% to 90.9% of fully diluted equity.
Corrected Certificate of Designation increases Series A Preferred designated shares from 7,263,865 to 7,477,017.
Amendment to Securities Purchase Agreement extends Initial Closing date and expands investor notification rights.

item 1.01item 3.03item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.